Endo Health Solutions Inc. (ENDP)

Check out top investors' recommendation for ENDP
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology. Its Qualitest segment provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. The company’s AMS segment offers various technology solutions comprising AMS 700 MS series, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, Elevate transvaginal pelvic floor repair system, and Monarc subfascial hammock products in the areas of men’s and women’s health, and BPH therapy. Its HealthTronics segment provides urological services, such as lithotripsy, prostate treatment, anatomical pathology, and electronic medical record services to urologists, hospitals, surgery centers, and clinics; and manufactures, sells, and maintains medical devices for tissue and tumor ablation. The company’s products under development primarily include Aveed, an injectable testosterone preparation to treat male hypogonadism; BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain; ODM-201, an androgen receptor antagonist in Phase II clinical testing to treat castrate resistant prostate cancer; and EN3342, a polyurethane implant in Phase I/II trials for the maintenance treatment of schizophrenia in adults. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. The company was formerly known as Endo Pharmaceuticals Holdings Inc. and changed its name to Endo Health Solutions Inc. in May 2012. Endo Health Solutions Inc. was founded in 1997 and is headquartered in Malvern, Pennsylvania.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Randall Stanicky Canaccord Genuity Buy   Aug 13, '18     26.00  Aug 13, '19  N/A 
Ami Fadia UBS Buy   Aug 09, '18     18.00  Aug 09, '19  N/A 
Liav Abraham Citi Buy   Aug 09, '18     19.00  Aug 09, '19  N/A 
David Buck Shore Capital Buy   Aug 06, '18     15.00  Aug 06, '19  N/A 
Liav Abraham Citi Buy   Jun 27, '18       Jun 27, '19  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Jun 01, '18     10.00  Jun 01, '19  N/A 
David Buck Shore Capital Buy   May 21, '18     10.00  May 21, '19  N/A 
David Buck Shore Capital Buy   Mar 22, '18     10.00  Mar 22, '19  N/A 
David Buck Shore Capital Buy   Feb 13, '18     10.00  Feb 13, '19  N/A 
Ami Fadia UBS Buy   Jan 02, '18     12.00  Jan 02, '19  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Aug 09, '17     13.00  Aug 09, '18  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Jul 07, '17     15.00  Jul 07, '18  N/A 
Gary Nachman Susquehanna Financial Group Buy   Jan 31, '17       Jan 31, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   May 18, '16     25.00  May 18, '17  N/A 
Randall Stanicky Canaccord Genuity Buy   Mar 01, '16   42.19  73.00  Mar 01, '17  -67.65% 
Corey Davis Jefferies & Co. Buy   Mar 01, '16   42.19  67.00  Mar 01, '17  -67.65% 
Chris Schott JPMorgan Buy   Mar 01, '16   42.19  80.00  Mar 01, '17  -67.65% 
Jason Gerberry Leerink Swann Llc Buy   Mar 01, '16   42.19  51.00  Mar 01, '17  -67.65% 
David Amsellem Piper Jaffray Buy   Mar 01, '16   42.19  81.00  Mar 01, '17  -67.65% 
Shibani Malhotra RBC Capital Markets Buy   Feb 29, '16   41.81  95.00  Feb 28, '17  -68.21% 
< previous1234